Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant Staphylococcus aureus bacteremia

Mitchell J. Schwaber, Sharon B. Wright, Yehuda Carmeli, Lata Venkataraman, Paola C. DeGirolami, Aneta Gramatikova, Trish M. Perl, George Sakoulas, Howard S. Gold

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

We conducted a retrospective study of the clinical aspects of bacteremia caused by methicillin-resistant Staphylococcus aureus (MRSA) with heterogeneously reduced susceptibility to vancomycin. Bloodstream MRSA isolates were screened for reduced susceptibility by using brain-heart infusion agar, including 4 mg/L vancomycin with and without 4% NaCl. Patients whose isolates exhibited growth (case-patients) were compared with those whose isolates did not (controls) for demographics, coexisting chronic conditions, hospital events, antibiotic exposures, and outcomes. Sixty-one (41%) of 149 isolates exhibited growth. Subclones from 46 (75%) of these had a higher MIC of vancomycin than did their parent isolates. No isolates met criteria for vancomycin heteroresistance. No differences in potential predictors or in outcomes were found between case-patients and controls. These data show that patients with vancomycin-susceptible MRSA bacteremia have similar baseline clinical features and outcomes whether or not their bacterial isolates exhibit growth on screening media containing vancomycin.

Original languageEnglish (US)
Pages (from-to)657-664
Number of pages8
JournalEmerging Infectious Diseases
Volume9
Issue number6
StatePublished - Jun 1 2003

Fingerprint

Vancomycin
Methicillin-Resistant Staphylococcus aureus
Bacteremia
Growth
Agar
Retrospective Studies
Demography
Anti-Bacterial Agents
Brain

ASJC Scopus subject areas

  • Epidemiology
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Schwaber, M. J., Wright, S. B., Carmeli, Y., Venkataraman, L., DeGirolami, P. C., Gramatikova, A., ... Gold, H. S. (2003). Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant Staphylococcus aureus bacteremia. Emerging Infectious Diseases, 9(6), 657-664.

Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant Staphylococcus aureus bacteremia. / Schwaber, Mitchell J.; Wright, Sharon B.; Carmeli, Yehuda; Venkataraman, Lata; DeGirolami, Paola C.; Gramatikova, Aneta; Perl, Trish M.; Sakoulas, George; Gold, Howard S.

In: Emerging Infectious Diseases, Vol. 9, No. 6, 01.06.2003, p. 657-664.

Research output: Contribution to journalArticle

Schwaber, MJ, Wright, SB, Carmeli, Y, Venkataraman, L, DeGirolami, PC, Gramatikova, A, Perl, TM, Sakoulas, G & Gold, HS 2003, 'Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant Staphylococcus aureus bacteremia', Emerging Infectious Diseases, vol. 9, no. 6, pp. 657-664.
Schwaber MJ, Wright SB, Carmeli Y, Venkataraman L, DeGirolami PC, Gramatikova A et al. Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant Staphylococcus aureus bacteremia. Emerging Infectious Diseases. 2003 Jun 1;9(6):657-664.
Schwaber, Mitchell J. ; Wright, Sharon B. ; Carmeli, Yehuda ; Venkataraman, Lata ; DeGirolami, Paola C. ; Gramatikova, Aneta ; Perl, Trish M. ; Sakoulas, George ; Gold, Howard S. / Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant Staphylococcus aureus bacteremia. In: Emerging Infectious Diseases. 2003 ; Vol. 9, No. 6. pp. 657-664.
@article{6622a89493dc49b1a6cc0322fdc0394d,
title = "Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant Staphylococcus aureus bacteremia",
abstract = "We conducted a retrospective study of the clinical aspects of bacteremia caused by methicillin-resistant Staphylococcus aureus (MRSA) with heterogeneously reduced susceptibility to vancomycin. Bloodstream MRSA isolates were screened for reduced susceptibility by using brain-heart infusion agar, including 4 mg/L vancomycin with and without 4{\%} NaCl. Patients whose isolates exhibited growth (case-patients) were compared with those whose isolates did not (controls) for demographics, coexisting chronic conditions, hospital events, antibiotic exposures, and outcomes. Sixty-one (41{\%}) of 149 isolates exhibited growth. Subclones from 46 (75{\%}) of these had a higher MIC of vancomycin than did their parent isolates. No isolates met criteria for vancomycin heteroresistance. No differences in potential predictors or in outcomes were found between case-patients and controls. These data show that patients with vancomycin-susceptible MRSA bacteremia have similar baseline clinical features and outcomes whether or not their bacterial isolates exhibit growth on screening media containing vancomycin.",
author = "Schwaber, {Mitchell J.} and Wright, {Sharon B.} and Yehuda Carmeli and Lata Venkataraman and DeGirolami, {Paola C.} and Aneta Gramatikova and Perl, {Trish M.} and George Sakoulas and Gold, {Howard S.}",
year = "2003",
month = "6",
day = "1",
language = "English (US)",
volume = "9",
pages = "657--664",
journal = "Emerging Infectious Diseases",
issn = "1080-6040",
publisher = "Centers for Disease Control and Prevention (CDC)",
number = "6",

}

TY - JOUR

T1 - Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant Staphylococcus aureus bacteremia

AU - Schwaber, Mitchell J.

AU - Wright, Sharon B.

AU - Carmeli, Yehuda

AU - Venkataraman, Lata

AU - DeGirolami, Paola C.

AU - Gramatikova, Aneta

AU - Perl, Trish M.

AU - Sakoulas, George

AU - Gold, Howard S.

PY - 2003/6/1

Y1 - 2003/6/1

N2 - We conducted a retrospective study of the clinical aspects of bacteremia caused by methicillin-resistant Staphylococcus aureus (MRSA) with heterogeneously reduced susceptibility to vancomycin. Bloodstream MRSA isolates were screened for reduced susceptibility by using brain-heart infusion agar, including 4 mg/L vancomycin with and without 4% NaCl. Patients whose isolates exhibited growth (case-patients) were compared with those whose isolates did not (controls) for demographics, coexisting chronic conditions, hospital events, antibiotic exposures, and outcomes. Sixty-one (41%) of 149 isolates exhibited growth. Subclones from 46 (75%) of these had a higher MIC of vancomycin than did their parent isolates. No isolates met criteria for vancomycin heteroresistance. No differences in potential predictors or in outcomes were found between case-patients and controls. These data show that patients with vancomycin-susceptible MRSA bacteremia have similar baseline clinical features and outcomes whether or not their bacterial isolates exhibit growth on screening media containing vancomycin.

AB - We conducted a retrospective study of the clinical aspects of bacteremia caused by methicillin-resistant Staphylococcus aureus (MRSA) with heterogeneously reduced susceptibility to vancomycin. Bloodstream MRSA isolates were screened for reduced susceptibility by using brain-heart infusion agar, including 4 mg/L vancomycin with and without 4% NaCl. Patients whose isolates exhibited growth (case-patients) were compared with those whose isolates did not (controls) for demographics, coexisting chronic conditions, hospital events, antibiotic exposures, and outcomes. Sixty-one (41%) of 149 isolates exhibited growth. Subclones from 46 (75%) of these had a higher MIC of vancomycin than did their parent isolates. No isolates met criteria for vancomycin heteroresistance. No differences in potential predictors or in outcomes were found between case-patients and controls. These data show that patients with vancomycin-susceptible MRSA bacteremia have similar baseline clinical features and outcomes whether or not their bacterial isolates exhibit growth on screening media containing vancomycin.

UR - http://www.scopus.com/inward/record.url?scp=0038049117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038049117&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 657

EP - 664

JO - Emerging Infectious Diseases

JF - Emerging Infectious Diseases

SN - 1080-6040

IS - 6

ER -